Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(2):173-5
Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
Authors Information

1Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, United Kingdom

2Centre for Epidemiology versus Arthritis, University of Manchester, Manchester, United Kingdom

AY Gasparyan, GD Kitas

References
  1. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med 2020;383(23):2255-73.
  2. Guo Y, Li T, Xia X, Su B, Li H, Feng Y, et al. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. Front Immunol 2021;12:723585.
  3. Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol 2020;16(8):465-470.
  4. Bonnet B, Cosme J, Dupuis C, Coupez E, Adda M, Calvet L, et al. Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation. EBioMedicine 2021;73:103622.
  5. Sefik E, Qu R, Junqueira C, Kaffe E, Mirza H, Zhao J, et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 2022. doi: 10.1038/s41586-022-04802-1. Online ahead of print.
  6. Taha SI, Samaan SF, Ibrahim RA, El-Sehsah EM, Youssef MK. Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity? Eur Cytokine Netw 2021;32(4):83-8.
  7. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020;80(4):527-38.
  8. Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al; ARTIS Study Group. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 2021;80(8):1086-93.
  9. Qi G, Wang H, Guo Y, Peng C, Zhang C, Chen T, He J, Jin Z. Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China. Clin Rheumatol 2022;41(6):1899-1910.
  10. Alzahrani ZA, Alghamdi KA, Almaqati AS. Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. Rheumatol Int 2021;41(6):1097-1103.
  11. Gamboa-Cárdenas RV, Barzola-Cerrón S, Toledo-Neira D, Reátegui-Sokolova C, Pimentel-Quiroz V, Zevallos-Miranda F, et al. Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clin Rheumatol 2021;40(11):4725-34.
  12. Buckley LF, Wohlford GF, Ting C, Alahmed A, Van Tassell BW, Abbate A, et al. Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. Crit Care Explor 2020;2(8):e0178.
  13. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med 2020;383(24):2333-2344.
  14. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021;384(16):1491-502.
  15. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397(10285):1637-45.
  16. Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis Rheumatol 2020;72(12):1990-7.
  17. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 2021;27(10):1752-60.
  18. Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, Barbetta L, et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. J Allergy Clin Immunol 2021;147(2):561-566.e4.
  19. CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021;9(3):295-304.
  20. Stella A, Lamkanfi M, Portincasa P. Familial Mediterranean Fever and COVID-19: Friends or Foes? Front Immunol 2020;11:574593.
  21. Günendi Z, Yurdakul FG, Bodur H, Cengiz AK, Uçar Ü, Çay HF, et al. The impact of COVID-19 on familial Mediterranean fever: a nationwide study. Rheumatol Int 2021;41(8):1447-55.
  22. Güven SC, Erden A, Karakaş Ö, Armağan B, Usul E, Omma A, et al. COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study. Rheumatol Int 2021;41(4):715-9.
  23. Bourguiba R, Kyheng M, Koné-Paut I, Rouzaud D, Avouac J, Devaux M, et al; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases. RMD Open 2022;8(1):e002063.
  24. Davidson M, Menon S, Chaimani A, Evrenoglou T, Ghosn L, Graña C, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev 2022;1(1):CD015308.
  25. Tzioufas AG, Bakasis AD, Goules AV, Bitzogli K, Cinoku II, Chatzis LG, et al. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun 2021;125:102743.